Granted Patent
B2
US 11,690,915 · App. 17/476,269 · Granted Jul 4, 2023
Ras inhibitors
Inventors:
Naing Aay (San Mateo, CA); G. Leslie Burnett (Redwood City, CA); James Cregg (Belmont, CA); Adrian L. Gill (Atherton, CA); John E. Knox (Emerald Hills, CA); Elena S. Koltun (Foster City, CA); Yang Liu (Foster City, CA); Andreas Buckl (San Francisco, CA); Bianca Jennifer Lee (Redwood City, CA); David E. Wildes (San Francisco, CA); Meghan A. Rice (Belmont, CA); Mallika Singh (San Francisco, CA)
Assignee:
Revolution Medicines, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims (2)
1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
2. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable excipient.
Assignments (2)
SECURITY INTEREST
Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 6, 2022
From: AAY, NAING; BURNETT, G. LESLIE; CREGG, JAMES; GILL, ADRIAN L.; KNOX, JOHN E.; KOLTUN, ELENA S.; LIU, YANG; BUCKL, ANDREAS; LEE, BIANCA JENNIFER; WILDES, DAVID E.; RICE, MEGHAN A.; SINGH, MALLIKA
To: REVOLUTION MEDICINES, INC.
Reel/Frame 059518/0440 →
Continuity (5)
Provisional Application
63192775
· May 25, 2021
Provisional Application
63184412
· May 5, 2021
Provisional Application
63129231
· Dec 22, 2020
Provisional Application
63078802
· Sep 15, 2020